Lonafarnib in Metastatic Breast Cancer

Exclusion Criteria

• •No history or radiologic evidence of CNS metastases including previously treated, resected or asymptomatic brain lesions or leptomeningeal involvement (head CT or MRI must be obtained within 42 days prior to registration for protocol therapy).
• •No treatment with any investigational agent within 30 days prior to registration for protocol therapy.
• •No history of Torsades de Pointes, ventricular tachycardia, ventricular fibrillation or ventricular flutter.
• •No history of syncope.
• •No history of seizures.
• •No prolonged QTc interval \> 450msec on pre-entry electrocardiogram obtained within 28 days prior to registration for protocol therapy.
• •No history of hypokalemia that cannot be corrected prior to registration for protocol therapy.
• •No radiation within 14 days prior to registration for protocol therapy. Patients must have recovered from the acute toxic effects prior to registration for protocol therapy.
• •No prior chemotherapy within 21 days prior to registration for protocol therapy.
• •No clinically active serious infections as judged by the treating investigator (CTC v3, \> Grade 2) including known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
• •Following concomitant medications must be discontinued 7 days prior to registration for protocol therapy and for the duration of lonafarnib therapy: bisphosphonates, including but not limited to etidronate (Didronel), pamidronate (Aredia), alendronate (Fosamax), risedronate (Actonel), zoledronate (Zometa or Reclast), ibandronate (Boniva), ethinylestradiol, gestodene, itraconazole, ketoconazole, cimetidine, erythromycin, carbamazepine, high dose chronic steroids, phenobarbital, phenytoin, rifampin (rifampicin), sulfinpyrazone